All In Biotech

NDA 212516 · Sun Pharm

Drizalma Sprinkle

Duloxetine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Aug 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jul 19, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

410

121 Phase 3, 33 recruiting

FAERS reports

52,942

38,285 serious, 5,746 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)] . WARNING: SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. • Increased risk of suicidal thinking and behavior in pediatric and young adult patients taking antidepressants (5.1) • Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors (5.1)

What it is approved for

From the label in effect May 14, 2024.

DRIZALMA SPRINKLE is indicated for the treatment of: • Major Depressive Disorder in adults • Generalized Anxiety Disorder in adults and pediatric patients 7 years of age and older • Diabetic Peripheral Neuropathy in adults • Fibromyalgia in adults • Chronic Musculoskeletal Pain in adults Additional pediatric use information is approved for Eli Lilly and Company, Inc.’s CYMBALTA (duloxetine delayed-release capsules). However, due to Eli Lilly and Company Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. DRIZALMA SPRINKLE is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of following conditions: • Major Depressive Disorder (MDD) in adults (1) • Generalized Anxiety Disorder (GAD) in adults and pediatric patients ages 7 years of age and older (1) • Diabetic Peripheral Neuropathic Pain (DPNP) in adults (1) • Fibromyalgia (FM) in adults (1) • Chronic Musculoskeletal Pain in adults (1)

Mechanism: Although the exact mechanisms of the antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 23, 2021 Supplement 2 · Efficacy LabelLetter
  • Jul 19, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
4 products under this application
  • DRIZALMA SPRINKLE · DULOXETINE HYDROCHLORIDE EQ 40MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription
  • DRIZALMA SPRINKLE · DULOXETINE HYDROCHLORIDE EQ 20MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription
  • DRIZALMA SPRINKLE · DULOXETINE HYDROCHLORIDE EQ 60MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription
  • DRIZALMA SPRINKLE · DULOXETINE HYDROCHLORIDE EQ 30MG BASE · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Duloxetine" as an intervention, any sponsor and status, largest first.

All 410 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,198
  • fatigue3,892
  • nausea3,793
  • off label use3,210
  • pain2,934
  • headache2,804
  • diarrhoea2,737
  • dizziness2,319
  • fall2,246
  • vomiting2,032
  • toxicity to various agents1,892
  • arthralgia1,876

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200523
200642
200772
2008145
200992
2010129
2011149
2012124
2013382
20141,019
20151,785
20162,557
20173,266
20184,324
20195,068
20205,408
20214,825
20224,822
20234,722
20244,707
20255,172
20264,109

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Drizalma Sprinkle (Duloxetine HCl)

2024 spending

$1.2M

Beneficiaries

2,478

6,429 claims

Per beneficiary

$480

$7.14 per unit

View as table
YearSpending
2020$1,834,392
2021$4,146,026
2022$45,630
2023$9,375
2024$1,188,637

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 802 on PubMed

Sponsor: Sun Pharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.